News Related to oHCM

Related coverage linked through entity extraction aliases.

Cytokinetics Launches MYQORZO; C4 Therapeutics Advances Cemsidomide Trial

Feb 25, 2026

Cytokinetics launches MYQORZO for obstructive hypertrophic cardiomyopathy following FDA approval, while C4 Therapeutics doses first patient in Phase 2 trial of cemsidomide for relapsed/refractory multiple myeloma.

European Commission Approves MYQORZO for Obstructive Hypertrophic Cardiomyopathy

Feb 17, 2026

The European Commission approved MYQORZO (aficamten) for treating symptomatic obstructive hypertrophic cardiomyopathy in adults, completing global regulatory approvals following FDA and China NMPA clearances. First European launch planned in Germany in Q2 2026.